COVID-19 Outcomes in Kidney Transplant Recipients Receiving Tixagevimab/Cilgavimab for Pre-exposure Prophylaxis: A Single-center Retrospective Study
These real-world data show that pre-exposure prophylaxis with tixagevimab/cilgavimab was a feasible alternative for patients without sufficient serological response to vaccination during a period of Omicron dominance. Novel therapeutics are necessary for variants resistant to tixagevimab/cilgavimab.
Authors
- Friederike Bachmann (ORCID: https://orcid.org/0000-0001-7728-9875)
- Marcel G. Naik (ORCID: https://orcid.org/0000-0002-6063-2806)
- Bilgin Osmanodja (ORCID: https://orcid.org/0000-0002-8660-0722)
- Wiebke Duettmann (ORCID: https://orcid.org/0000-0002-0275-766X)
- Eva Vanessa Schrezenmeier (ORCID: https://orcid.org/0000-0002-0016-7885)
- Bianca Zukunft
- Mira Choi (ORCID: https://orcid.org/0000-0002-0286-1491)
- Klemens Budde (ORCID: https://orcid.org/0000-0002-7929-5942)
- Michael Mikhailov (ORCID: https://orcid.org/0000-0002-7624-9668)
- Fabian Halleck (ORCID: https://orcid.org/0000-0001-9449-2058)
- Geοrgiοs Eleftheriadis (ORCID: https://orcid.org/0000-0001-9877-9013)
- Jakob Joachim Spencker
Institutions
- Humboldt-Universität zu Berlin (DE)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Transplantation Proceedings
- Published
- 2025-09-17
- DOI
- https://doi.org/10.1016/j.transproceed.2025.06.021
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00